Myriad_MELARIS_logo

 

MELARIS® testing assesses a person’s risk of developing hereditary melanoma by detecting inherited mutations in the p16 gene (also called CDKN2A or INK4A), which is associated with hereditary melanoma and pancreatic cancer. Changes in the p16 gene increase cancer risk, making a melanoma diagnosis up to 50 times more likely by age 50.

MELARIS® is a simple blood test that determines whether a patient has a mutation in the p16 gene. Knowing the results of the MELARIS® test may help patients and their act before cancer has had a chance to develop.

Myriad has developed a Hereditary Cancer Quiz that patients and can use to help identify potential candidates for genetic testing using MELARIS®.

Benefits of MELARIS® Testing

For patients with a p16 gene mutation, the result of the MELARIS® test enables the healthcare professional to develop an individualized medical management plan to significantly reduce the risk of cancer.  MELARIS® helps healthcare professionals to:

  • Personalize patient care and increase clinical efficiency by targeting screening and surveillance specifically to individuals with a p16 gene mutation;
  • Improve patient compliance with tailored screening recommendations and preventive measures;
  • Improve outcomes through earlier diagnosis and treatment of cancer;
  • Counsel patients and their family members on the underlying cause of the pattern of melanoma and possibly pancreatic cancer; and
  • Avoid unnecessary interventions for family members who do not test positive for the mutation known to be in the family.

Medical Management and MELARIS®

If the MELARIS® test shows an increased risk for hereditary melanoma and pancreatic cancer, the following medical management options may help reduce that risk.

Melanoma:

  • Increased surveillance
  • Preventive lifestyle adjustments
  • Lower threshold for biopsy

Pancreatic Cancer:

  • Increased surveillance

For more healthcare professional information or to order a MELARIS® test kit, please visit MyriadPro.com.

NOTE: Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare professional.